Injection

Bortezomib 3.5mg

Bortezomib

First-in-class reversible 26S proteasome inhibitor that disrupts protein homeostasis in malignant plasma cells and lymphoma cells, leading to accumulation of pro-apoptotic proteins and tumour cell death. It is a backbone agent in VRd and VCD regimens for newly diagnosed multiple myeloma and is approved for relapsed mantle cell lymphoma. Cipla and Hetero Drugs supply 2mg and 3.5mg lyophilized vials for IV or subcutaneous administration, exported globally to haematology units.

Strengths

2mg / 3.5mg

Packing

1 vial/box

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Bortezomib 2mg / 3.5mg lyophilized powder for injection

Dosage Form

Injection

Available Strengths

2mg / 3.5mg

Packing

1 vial/box

Route of Administration

Intravenous (IV push) or Subcutaneous

Dosage

1.3mg/m2 on days 1, 4, 8, 11 of a 21-day cycle for up to 8 cycles

Indications

Previously untreated multiple myeloma, relapsed/refractory multiple myeloma, relapsed/refractory mantle cell lymphoma

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 25°C, protect from light; reconstituted solution: use within 8 hours

Shelf Life

24 months

Side Effects

Peripheral neuropathy, thrombocytopenia, neutropenia, fatigue, nausea, diarrhea, constipation

Precautions

Monitor for peripheral neuropathy (dose modify or discontinue); platelet counts nadir on day 11; risk of tumor lysis syndrome; avoid in severe hepatic impairment

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Tablet

Sorafenib 200mg

Sorafenib Tosylate

Soranib (Sorafenib 200mg) is an oral anti-cancer medicine that works by blocking abnormal protein signals that cause cancer cells to multiply. It helps stop or slow the spread of cancer in hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Available for global pharmaceutical export with WHO-GMP certification.

200mg

Capsule

Lenalidomide 25mg

Lenalidomide

Lenalid (Lenalidomide 25mg) is an anti-cancer medicine that works by enhancing the immune system to attack cancer cells while preventing growth of new blood vessels within tumors. It is used for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Available in 5mg, 10mg, and 25mg capsule strengths for global pharmaceutical export.

5mg / 10mg / 25mg

Tablet

Imatinib 400mg

Imatinib Mesylate

First-in-class BCR-ABL tyrosine kinase inhibitor that transformed CML from a fatal disease into a chronically manageable condition, achieving complete cytogenetic response in over 80% of newly diagnosed chronic-phase patients. It also targets c-KIT and PDGFR, making it the standard first-line treatment for unresectable or metastatic GIST and Ph+ ALL. Cipla and Sun Pharma manufacture affordable Indian generics in both 100mg and 400mg tablet strengths exported to oncology programmes worldwide.

100mg / 400mg

Need bulk pricing for Bortezomib 3.5mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote